[Drug selection guided by known and newly diagnosed comorbidities in a multi-risk patient].
The obese patient with osteoarthritis, arterial hypertension, type 2 diabetes, hyperuricaemia, mixed dyslipidaemia and moderate renal insufficiency is commonly seen in clinical practice. Besides life-style changes, the optimal management of such patient requires the use of a polymedication therapy whose choice should take into account not only possible pharmacological synergistic effects to warrant the best protection, but also contra-indications due to the presence of comorbidities or the risk of drug interferences.
Scheen
A J
AJ
Université de Liège, Service de Diabétologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU de Liège, Belgique.
D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D050171:Dyslipidemias / Q000150:complications*; D006801:Humans; D006973:Hypertension / Q000150:complications*; D033461:Hyperuricemia / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications*; D010003:Osteoarthritis / Q000150:complications*; D019338:Polypharmacy; D051437:Renal Insufficiency / Q000150:complications*